Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis

被引：8
|
作者：
Christopher, Karen L. [1 ]
Elner, Victor M. [1 ]
Demirci, Hakan [1 ]
机构：
[1] Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48109 USA
来源：
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY | 2017年 / 33卷 / 03期
关键词：
B-CELL LYMPHOMA; RITUXIMAB;
D O I：
10.1097/IOP.0000000000000774
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
The authors describe a 39-year-old woman treated with fingolimod for relapsing-remitting multiple sclerosis for 2 years who then developed a bilateral conjunctival mucosa-associated lymphoid tissue lymphoma. Fingolimod treatment for multiple sclerosis has been associated with lymphoma in 3 previously reported cases. This is the first case of ocular adnexal lymphoma presumed to be due to fingolimod. Given that ophthalmologists regularly monitor many patients on fingolimod for fingolimod-associated macular edema and ophthalmic manifestations of multiple sclerosis, the authors hope to alert physicians of the possibility of ocular adnexal lymphoma in these patients.
引用
收藏
页码：E73 / E75
页数：3
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
    Mehdi Rezaee
    Mohammad Hossein Morowvat
    Maryam Poursadeghfard
    Armin Radgoudarzi
    Khosro Keshavarz
    BMC Health Services Research, 22
  • [42] Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS
    de Flon, Pierre
    Laurell, Katarina
    Soderstrom, Lars
    Gunnarsson, Martin
    Svenningsson, Anders
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (09) : 1249 - 1257
  • [43] Ofatumumab for relapsing forms of multiple sclerosis
    Gajofatto, Alberto
    Orlandi, Riccardo
    DRUGS OF TODAY, 2022, 58 (01) : 9 - 21
  • [44] Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
    Boremalm, M.
    Juto, A.
    Axelsson, M.
    Novakova, L.
    Frisell, T.
    Svenningsson, A.
    Lycke, J.
    Piehl, F.
    Selzer, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (08) : 1060 - 1067
  • [45] Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review
    Brown, Justin D.
    Muston, Benjamin T.
    Massey, Jennifer
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 86
  • [46] Rituximab combination therapy in relapsing multiple sclerosis
    Cross, Anne H.
    Klein, Robyn S.
    Piccio, Laura
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2012, 5 (06) : 311 - 319
  • [47] B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses
    Ireland, Sara J.
    Guzman, Alyssa A.
    Frohman, Elliot M.
    Monson, Nancy L.
    JOURNAL OF NEUROIMMUNOLOGY, 2016, 291 : 46 - 53
  • [48] Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
    Nygaard, Gro Owren
    Torgauten, Hilde
    Skattebol, Lars
    Hogestol, Einar August
    Sowa, Piotr
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    Celius, Elisabeth Gulowsen
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 62
  • [49] A Special Case of Relapsing-Remitting Bilateral Encephalitis: Without Epilepsy, but Responding to Rituximab and with a Brain Biopsy Coinciding with Rasmussen Encephalitis
    Liu, Pei
    Lin, Xuemei
    Zong, Shenghua
    Yan, Yan
    Liu, Zhongzhong
    Lu, Qingli
    Chang, Qiaoqiao
    Wu, Songdi
    BRAIN SCIENCES, 2023, 13 (01)
  • [50] Comparative effectiveness of rituximab relative to IFN- or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry
    Spelman, Tim
    Frisell, Thomas
    Piehl, Fredrik
    Hillert, Jan
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (08) : 1087 - 1095
12345